北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
作者: Yao, L.1; Liu, Y.2; Li, Z.1; Ouyang, T.1; Li, J.1; Wang, T.1; Fan, Z.1; Fan, T.1; Lin, B.1; Xie, Y.1
关键词: anthracycline ; breast cancer ; HER2 ; neoadjuvant chemotherapy
刊名: ANNALS OF ONCOLOGY
发表日期: 2011-06-01
DOI: 10.1093/annonc/mdq612
卷: 22, 期:6, 页:1326-1331
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: SURGICAL ADJUVANT BREAST ; PREOPERATIVE CHEMOTHERAPY ; SYSTEMIC THERAPY ; RANDOMIZED-TRIALS ; DOXORUBICIN ; WOMEN ; DOCETAXEL ; CYCLOPHOSPHAMIDE ; SENSITIVITY ; EXPRESSION
英文摘要:

Background: The predictive role of human epidermal growth factor receptor 2 (HER2) to adjuvant anthracycline-based chemotherapy remains controversial. Here, we investigated the association between HER2 status and pathological response in breast cancer patients who received neoadjuvant anthracycline-based regimens.

Patients and methods: Women (n = 538) with operable primary breast cancer received neoadjuvant anthracycline-based chemotherapy. Pathological complete response (pCR) was defined as no invasive breast tumor cells in breast after completion of neoadjuvant chemotherapy. HER2 status was determined by immunohistochemistry and/or by fluorescence in situ hybridization in core biopsy breast cancer tissue obtained before initiation of neoadjuvant chemotherapy.

Results: In this cohort of 538 patients, 23.9% of patients achieved a pCR in their breast. HER2-positive tumors had a lower rate of pCR than did HER2-negative tumors (14.7% versus 25.7%, P = 0.013); negative HER2 status remained as an independent favorable predictor of pCR after adjusted for age, estrogen receptor, progesterone receptor, tumor size, chemotherapy cycles, and tumor grade in a multivariate analysis (odds ratio = 3.14; 95% confidence interval = 1.60-6.16, P = 0.001). Furthermore, patients with a pCR had a higher 3-year disease-free survival (DFS) rate than did patients without a pCR (P = 0.007).

Conclusion: Women with HER2-negative breast cancers rather than HER2-positive tumors benefit from anthracycline-based neoadjuvant chemotherapy.

语种: 英语
所属项目编号: 30973436
项目资助者: Program for Breast Cancer Tissue Bank of Beijing ; National Natural Science Foundation of China
WOS记录号: WOS:000291060800012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/62330
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst, Breast Ctr, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst,Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Yao, L.,Liu, Y.,Li, Z.,et al. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer[J]. ANNALS OF ONCOLOGY,2011,22(6):1326-1331.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yao, L.]'s Articles
[Liu, Y.]'s Articles
[Li, Z.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yao, L.]‘s Articles
[Liu, Y.]‘s Articles
[Li, Z.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace